Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Tabrecta FCT
| Field | Information |
|---|---|
| Medication Name | Tabrecta FCT |
| Generic Name | Capmatinib |
| Boxed/Label Warning | May cause embryo-fetal toxicity. Females of reproductive potential should use effective contraception during treatment and for 2 weeks after the final dose. |
| Purpose | A kinase inhibitor used to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a MET exon 14 skipping alteration. |
| Mechanism of Action | Capmatinib is a selective MET inhibitor that inhibits MET phosphorylation and MET-dependent signaling. |
| Dosage Forms | Film-coated tablets |
| Available Strengths | 150 mg, 200 mg |
| Dosage Frequency | 400 mg orally twice daily |
| Common Side Effects | Peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite |
| Serious Side Effects | Interstitial lung disease (ILD)/pneumonitis, hepatotoxicity, hyperbilirubinemia, pancreatitis, photosensitivity |
| Drug Interactions | Strong CYP3A4 inhibitors (e.g., itraconazole), strong CYP3A4 inducers (e.g., rifampin) |
| Important Notes | Take with or without food. Do not crush, chew, or split tablets. Inform your doctor of any pre-existing liver or lung conditions. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C). |
| Missed Dose | If a dose is missed by more than 4 hours, skip the dose and take the next dose at the regularly scheduled time. Do not take two doses at one time to make up for the missed dose. |
| Alternatives | Selpercatinib, Tepotinib, Crizotinib, Entrectinib |
Tabrecta FCT Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Selpercatinib (Retevmo) | RET kinase inhibitor | Used for RET-altered cancers. |
| Tepotinib (Tepmetko) | MET kinase inhibitor | Another MET inhibitor targeting NSCLC with MET exon 14 skipping alterations. |
| Crizotinib (Xalkori) | ALK/ROS1/MET inhibitor | May be used in certain lung cancers with specific gene alterations. |
| Entrectinib (Rozlytrek) | TRK/ROS1/ALK inhibitor | Used for NTRK fusion-positive cancers. |
Tabrecta FCT Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Peripheral edema | Interstitial lung disease (ILD)/pneumonitis |
| Nausea | Hepatotoxicity |
| Fatigue | Hyperbilirubinemia |
| Vomiting | Pancreatitis |
| Dyspnea | Photosensitivity |
| Decreased appetite | Embryo-fetal toxicity |
Tabrecta FCT Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| MET Exon 14 Skipping NSCLC | 400 mg twice daily | 400 mg twice daily | Take with or without food. Swallow tablets whole; do not crush, chew, or split them. |
